Blood Advances
Papers 2183
1 page of 219 pages (2,183 results)
#1Inge van der Werf (VUmc: VU University Medical Center)H-Index: 3
#2Anna Wojtuszkiewicz (VUmc: VU University Medical Center)H-Index: 9
Last. Jeroen J.W.M. Janssen (VUmc: VU University Medical Center)H-Index: 21
view all 0 authors...
Splicing factor (SF) mutations are important contributors to the pathogenesis of hematological malignancies; however, their relevance in risk classification of acute myeloid leukemia (AML) warrants further investigation. To gain more insight into the characteristics of patients with AML carrying SF mutations, we studied their association with clinical features, cytogenetic and molecular abnormalities, and clinical outcome in a large cohort of 1447 patients with AML and high-risk myelodysplastic ...
#1Siyuan Xu (Fudan University)H-Index: 1
#2Siqing Wang (Fudan University)H-Index: 4
Last. Kankan Wang (SJTU: Shanghai Jiao Tong University)
view all 0 authors...
Epigenetic abnormalities are frequently involved in the initiation and progression of cancers, including acute myeloid leukemia (AML). A subtype of AML, acute promyelocytic leukemia (APL), is mainly driven by a specific oncogenic fusion event of promyelocytic leukemia-RA receptor fusion oncoprotein (PML-RARα). PML-RARα was reported as a transcription repressor through the interaction with nuclear receptor corepressor and histone deacetylase complexes leading to the mis-suppression of its target ...
#1Andriyana K. Bankova (Stanford University)
#2Wendy W. Pang (Stanford University)H-Index: 15
Last. Judith A. Shizuru (Stanford University)H-Index: 58
view all 5 authors...
Depletion of hematopoietic stem cells (HSC) is used therapeutically in many malignant and non-malignant blood disorders in the setting of a hematopoietic cell transplantation (HCT) to eradicate diseased HSC allowing donor HSC to engraft. Current treatments to achieve HSC elimination rely on modalities that cause DNA strand breakage (i.e., alkylators, radiation) resulting in multiple short-term and long-term toxicities, and sometimes even death. These risks have severely limited HCT utilization t...
#1Irina Bonzheim (University of Tübingen)H-Index: 21
#2Philip Sander (University of Tübingen)
Last. Melanie Büssgen (University of Tübingen)
view all 16 authors...
Vitreoretinal lymphoma (VRL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL) considered a variant of primary central nervous system lymphoma (PCNSL). Diagnosis of VRL requires examination of vitreous fluid, but cytologic differentiation from uveitis remains difficult. Due to its rarity and difficulty in obtaining diagnostic material, little is known about the genetic profile of VRL. The aim of our study was to investigate the mutational profile of a large series of primary and seconda...
#1Ashley C. Kramer (WSU: Wayne State University)H-Index: 10
#2Yuliana Astuti (UMN: University of Minnesota)H-Index: 1
Last. Erin E Nolan (UMN: University of Minnesota)
view all 15 authors...
Hematopoietic cell homing after hematopoietic cell transplant (HCT) is governed by several pathways involving marrow niche cells that are evoked after pre-HCT conditioning. To understand the factors that play a role in homing, we performed expression analysis on the zebrafish marrow niche cells following conditioning. We determined that the non-collagenous protein extracellular matrix related protein dermatopontin (Dpt) was upregulated seven-fold in response to irradiation. Studies in mice revea...
#1Victor M. Orellana-Noia (UVA: University of Virginia)H-Index: 3
#2Krista Isaac (University of Virginia Health System)H-Index: 1
Last. Brian T. Hill (Cleveland Clinic)H-Index: 27
view all 22 authors...
We performed a multicenter retrospective analysis across 10 US academic medical centers (2010 - 2018) to evaluate current treatment patterns and outcomes in patients age ≥60 with classical Hodgkin lymphoma (cHL). Among 244 eligible patients, median age was 68, 63% had advanced stage (III/IV), 14% had ECOG performance status (PS) 2-4, and 12% had documented loss of ≥1 activity of daily living (ADLs). Medical comorbidities were assessed by the Cumulative Illness Rating Scale - Geriatric (CIRS-G), ...
#1Stéphane Buhler (Geneva College)H-Index: 18
#2Helen Baldomero (University Hospital of Basel)H-Index: 42
Last. Urs SchanzH-Index: 26
view all 14 authors...
HLA compatibility is a key factor for survival after unrelated hematopoietic cell transplantation (HCT). HLA-A, B, C, DRB1 and DQB1 are usually matched between donor and recipient. By contrast, HLA-DPB1 mismatches are frequent although it is feasible to optimize donor selection and DPB1 matching with prospective typing. Yet, because classical DPB1 allele mismatches are often unavoidable, several biological models have been developed to predict the optimal DPB1 mismatch combination for less graft...
#1Satoshi Wakita (Nippon Medical School)H-Index: 11
#2Masahiro Sakaguchi (Nippon Medical School)H-Index: 11
view all 53 authors...
Mutations of CCAAT/enhancer binding protein alpha (CEBPAmu) are found in 10-15% of de novo acute myeloid leukemia (AML) cases. Double-mutated CEBPA (CEBPAdm) is associated with a favorable prognosis; however, single-mutated CEBPA (CEBPAsm) does not appear to improve prognosis. We investigated the CEBPAmu for prognosis in 1028 AML patients, registered in the Multi-center Collaborative Program for Gene Sequencing of Japanese AML. It was found that CEBPAmu in the basic leucine zipper domain (bZIP) ...
#1Xi-ying Ren (PKU: Peking University)H-Index: 1
#2Qiu-Sha Huang (PKU: Peking University)H-Index: 2
Last. Yishan Ye (ZJU: Zhejiang University)
view all 43 authors...
Intracranial hemorrhage (ICH) is a rare but fatal central nervous system complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, factors that are predictive of early mortality in patients who develop ICH after undergoing allo-HSCT have not been systemically investigated. From January 2008 to June 2020, 70 allo-HSCT patients with ICH diagnosis formed the derivation cohort. Forty-one allo-HSCT patients with ICH diagnosis were collected from 12 other medical centers...
#1Carolina PavlovskyH-Index: 9
Last. Nancy Delgado (Mexican Social Security Institute)
view all 20 authors...
Tyrosine kinase inhibitors (TKI) have dramatically changed the survival of chronic myeloid leukemia (CML) patients and treatment-free remission (TFR) has recently merged as a new goal of CML treatment. The aim of this work was to develop recommendations for TKI discontinuation in Latin America (LA), outside clinical trials. A working group of CML experts from LA discussed 22 questions regarding TFR and reached a consensus for TFR recommendations in the region. TFR is indicated in patients in fir...
Top fields of study
Cancer research